The University of Oxford is the academic lead institution for StemBANCC. This 5-year research programme involves academic and industry partners across 10 countries. Its objective is to develop human-induced pluripotent stem cells as a platform for drug discovery.
This ambitious project brings together internationally renowned scientists and clinicians to study and develop new therapies for 8 major diseases of our time: Alzheimer’s, Parkinson’s, Autism, Schizophrenia, Bipolar, Migraine, Pain and Diabetes.
StemBANCC in Oxford is a grouping of 8 departments and the world-leading MRC FGU and FMRIB. The project began in 2012, with the HeLEX team taking responsibility for developing the internal ethics and governance frameworks.
StemBANCC is a world-class research programme developing an unparalleled resource of induced pluripotent stem cells from patients with well characterized disorders. It aims to overcome current bottlenecks in stem cell re-programming and differentiation; identify molecular and cellular phenotypes of disease in stem cell models; and translate findings into novel drug screening efficacy and toxicity assays.